Heska Corporation (NASDAQ:HSKA) will be hosting a conference call at 11:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.heska.com
Earnings Expectation
Heska Corporation is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, HSKA to report 3Q20 loss of $ 0.33 per share. For the full year, analysts anticipate top line of $ 177.69 million, while looking forward to loss of $ 1.88 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 175.00 million ~ $ 185.00 million
Click Here For More Historical Outlooks Of Heska Corporation
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The companys Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops.
